Tachyphylaxis, Tolerance, & Withdrawal Post Treatment With Igalmi for Agitation in Schizophrenia or Bipolar Disorder
Status:
Completed
Trial end date:
2024-04-29
Target enrollment:
Participant gender:
Summary
This is an in-clinic, single arm, open-label study assessing tachyphylaxis, tolerance, and
withdrawal following repeated doses of Igalmi in adult males and females with agitation
associated with schizophrenia or bipolar disorder.